MedX Health Corp. Announces Closing of Initial Tranches of Non-Brokered Private Placement and Announces That Due to COVID-19 Delays It Will Postpone the Release of Its Annual Financial Statements and Related Disclosures

Not for Dissemination in the United States or for Distribution to U.S. Newswire Services

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that further to the Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 25,000,000 units at $0.12 per unit (“Unit”), to raise up to $3,000,000 that was announced on March 6, 2020, the closing of two tranches of that placement have taken place, the first on April 22, and the second on April 27, 2020, for a total of 9,908,006 units, raising a total of $1,188,960. Closings of further tranches of this non-brokered placement are anticipated during the course of the coming days. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. The securities issued on April 22 and April 27, 2020, will be restricted from trading for four months from their respective dates of issue.

In connection with this non-brokered private placement, agent’s warrants (“Agent’s Warrant(s)”), as described below, were also issued. Each Agent’s Warrant, which is non-transferable, is exercisable to acquire one Unit at $0.12 per Unit, at any time during the period of two years following the respective dates of issue. In connection with the April 22 and April 27 Closings, total cash commissions of $76,720 were paid and 342,000 Agent’s Warrants were issued.

Postponement of the release of Annual Financial Statements and related Disclosure due to COVID-19 related delays.

The Company is also providing an update on the status of the filing of its annual financial statements and accompanying management’s discussion and analysis, and related CEO and CFO certifications for the financial year ended December 31, 2019 (collectively "Annual Filings").

On March 18, 2020, the Canadian Securities Administrators (CSA) announced that they will provide issuers with a 45-day filing extension for filings required on or before June 1, 2020 to allow issuers the time needed to focus on the many other business and financial reporting implications of COVID-19. MedX will rely on this exemption with respect to the Annual Filings in accordance with Ontario Instrument 51-502, Temporary Exemption from Certain Corporate Finance Requirements and corresponding Instruments in the other jurisdictions in which the Company is a reporting issuer.

The Company is continuing to work diligently and expeditiously with its auditors to file the Annual Filings by no later than June 12, 2020. In the interim, management and other insiders of the Company are subject to a trading black-out policy that reflects the principles in section 9 of National Policy 11-207, Failure to-File Cease Trade Orders and Revocations in Multiple Jurisdictions.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200428006082/en/